Beam Therapeutics has presented the first clinical data on its base editing technology. | Beam Therapeutics has presented the ...

BEAM-101, a gene-editing stem cell therapy, showed early signs of efficacy among the first treated sickle cell patients in a ...

Beam Therapeutics enrolls 35 patients in BEACON trial for BEAM-101 in sickle cell disease, with promising early safety and ...

BEAM-101 seems to be competitive with approved sickle cell treatments, William Blair analysts said in a note to investors, ...

Editas Medicine announced proof-of-concept data for a gene-editing approach for sickle cell disease that doesn't need a stem ...

Beam Therapeutics' early clinical data shows promising results for sickle cell disease treatment using CRISPR gene editing tool. One patient died ...

The death, which investigators linked to a preparatory chemo treatment rather than Beam's medicine, highlights the risks of using decades-old transplant drugs alongside cutting-edge CRISPR medicines.

This oral medication is considered a first-line treatment for sickle cell disease, and can help reduce pain crises. Hydroxyurea causes the body to produce fetal hemoglobin, a type of hemoglobin ...

Detailed price information for Fulcrum Therapeutics Inc (FULC-Q) from The Globe and Mail including charting and trades.

The therapy led to higher levels of fetal hemoglobin and lower levels of sickle-shaped cells. Beam also said signs of red blood cell destruction had normalized for all four patients and there were ...

Beam Therapeutics (BEAM) has received a new Buy rating, initiated by William Blair analyst, Sami Corwin. Sami Corwin’s rating is based on ...